ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO770

Methods to Identify Novel, Repeatedly Measured Biomarkers of CKD Outcomes

Session Information

Category: CKD (Non-Dialysis)

  • 1901 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Liu, Qian, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Smith, Abigail R., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Mariani, Laura H., University of Michigan, Ann Arbor, Michigan, United States
  • Nair, Viji, University of Michigan, Ann Arbor, Michigan, United States
  • Zee, Jarcy, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
Background

Identifying novel biomarkers is critical to advancing diagnosis and treatment of CKD, but relies heavily on the statistical methods used. Inappropriate methods can lead to both false positive and false negative associations between biomarkers and outcomes. This study assessed accuracy of methods using computer simulations and compared biomarker effect estimates in NEPTUNE, a prospective cohort study of patients with glomerular disease.

Methods

We compared four methods for analyzing repeatedly measured biomarkers in Cox models: 1) baseline, that only uses the single baseline biomarker value, 2) time-dependent with last observation carried forward (LOCF), that assumes the biomarker is unchanged until the next value, 3) time-averaged, that averages the biomarker values over all follow up and uses that average as a baseline covariate, and 4) time-dependent cumulative average, that updates the average using biomarker values at or before each time point.

Results

Simulation results showed the time-averaged method often gave extremely biased, inaccurate results. In NEPTUNE, all assessed urinary biomarkers were positively associated with 40% reduction in eGFR. Compared to the LOCF method, the baseline method had 6-21% lower hazard ratios (HRs), and the time-averaged method had 3-32% higher HRs [figure]. For complete remission, Eotaxin and TIMP1 were negatively associated with the outcome, and PDGF-BB had little association. HRs from the time-averaged method were always higher (1-13%) than the LOCF method.

Conclusion

Different analytic methods resulted in markedly different results. Using inappropriate methods such as time-averaging can bias effect estimates, while other methods provide prognostic (baseline), additive (cumulative average), or instantaneous (LOCF) effects depending on the hypothesized underlying mechanism.

Funding

  • NIDDK Support